Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 14, 2019

Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer and Outcomes Based on COX-2 Expression and ER Status

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial
J. Clin. Oncol 2019 Jan 31;[EPub Ahead of Print], AS Hamy, S Tury, X Wang, J Gao, JY Pierga, S Giacchetti, E Brain, B Pistilli, M Marty, M Espié, G Benchimol, E Laas, M Laé, B Asselain, B Aouchiche, M Edelman, F Reyal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading